<DOC>
	<DOCNO>NCT01534546</DOCNO>
	<brief_summary>Peri-operative treatment locally advance gastric cancer ( LAGC ) always argue eastern western scholar . For patient clinical stage cT4b/N+M0 , cT4aN+M0 , prognosis rather poor , primary lesion might resectable time diagnosis . MAGIC study show pre-and post-operative chemotherapy 3 cycle ECF increase 13 % 5yOS compare surgery alone ; However , eastern study ACTS GC CLASSIC show TS-1 monotherapy XELOX ( oxaliplatin/capecitabine ) combination give adjuvant chemotherapy stage II III patient D2 surgery could achieve significant survival benefit . So whether perioperative post operative therapy beneficial LAGC patient lack data support prospective study . So prospective randomized phase III study , investigator aim compare survival benefit well safety SOX ( oxaliplatin/TS-1 ) perioperative therapy versus SOX XELOX postoperative therapy D2 dissection .</brief_summary>
	<brief_title>Phase III Study Compare Perioperative Chemotherapy Oxaliplatin Combined With S-1 ( SOX ) Versus SOX Oxaliplatin With Capecitabine ( XELOX ) Post-operative Chemotherapy Locally Advanced Gastric Adenocarcinoma With D2 Dissection</brief_title>
	<detailed_description>detailed discription protocol update Feb 2013 ; detail discription protocol update Apr 2013 ; detail discription protocol update Oct 2013 ;</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>sign write informed consent form age ≥ 18 year pathologically confirm gastric GEJ adenocarcinoma disease clinical stage resectable potentially resectable LAGC（T4ab/N+M0） No prior antitumor treatment allow , include chemotherapy , radiotherapy , immune therapy target therapy Adequate organ function define : Hematologic ANC ≥ 1.5*109/l Hemoglobin ≥ 9 g/dl Platelets ≥ 100*109/l Hepatic Albumin ≥ 30g/l Serum bilirubin ≤ 1.5×ULN AST ALT ≤ 2.5×ULN ALP ≤ 2.5×ULN TBIL ≤ 1.5×ULN Renal Serum Creatinine &lt; 1.5 ULN KPS ≥ 70 Adequate lung heart function Negative serum urine pregnant test within 7 day prior randomization childbearing age woman Sexually active male female willing practice contraception study 30 day end study . Refuse provide blood/tissue sample； With distant metastasis； Sexually active male female refuse practice contraception study 30 day end study . Known hypersensitivity reaction metabolic disorder fluorpyrimidines oxaliplatin； ≥ grade 1 peripheral neuropathy； History organ transplantation（including autologous bone marrow transplantation Peripheral stem cell transplantation）； Prior long term steroid therapy ( exclude short term steroid treatment complete prior &gt; 2 week study enrollment ) ； Patients central nervous system ( CNS ) disorder peripheral nervous system disorder psychiatric disease； Concurrent severe infection； unable swallow ; ( complete incomplete ) gastrointestinal obstruction ; gastrointestinal bleeding ; gastrointestinal perforation； Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety ( include current active hepatic , biliary , renal , respiratory disease , uncontrolled diabetes hypertension et al ) ； History malignancy . However , subject diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma , eligible； Known history uncontrolled symptomatic angina , uncontrolled arrhythmia hypertension , congestive heart failure , cardiac infarction within 6 month prior study enrollment , cardiac insufficiency； Person capacity ( legally ) inappropriate continue study treatment ethics/medical reasons；</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>DFS</keyword>
	<keyword>OS</keyword>
	<keyword>safety</keyword>
	<keyword>resectable locally advanced gastric carcinoma</keyword>
	<keyword>potentially resectable locally advanced gastric carcinoma</keyword>
</DOC>